The state of Tennessee currently has 12 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Nashville, Memphis, Knoxville and Chattanooga.
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
03/15/2024
Locations: Clinical Trials Center of Middle Tennessee, Franklin, Tennessee +2 locations
Conditions: Idiopathic Pulmonary Fibrosis
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Clinical Trials Center of Middle Tennessee, LLC, Franklin, Tennessee +1 locations
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/06/2024
Locations: Vanderbilt Lung Institute - One Hundred Oaks, Nashville, Tennessee +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: Clinical Trials Center of Middle Tennessee, Franklin, Tennessee +2 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
02/29/2024
Locations: Clinical Trials Center of Middle Tennessee, Franklin, Tennessee +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/23/2024
Locations: Clinical Trials Center of Middle Tennessee, Franklin, Tennessee
Conditions: Idiopathic Pulmonary Fibrosis
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
Recruiting
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
Gender:
All
Ages:
40 years and above
Trial Updated:
02/21/2024
Locations: Vanderbilt Unversity Medical Center ., Nashville, Tennessee
Conditions: Idiopathic Pulmonary Fibrosis
Mechanisms of Familial Pulmonary Fibrosis
Recruiting
This a prospective, longitudinal study of first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP). FIP is the familial form of idiopathic pulmonary fibrosis (IPF), which is defined as 2 or more bloodline relatives which have a diagnosis of idiopathic interstitial pneumonia (IIP). The most common form of idiopathic interstitial pneumonia in FIP families is IPF (approximately 70%). The inheritance pattern in FIP is consistent with autosomal dominant inheritance... Read More
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
12/11/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Familial Interstitial Pneumonia
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
11/24/2023
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Post Acute Sequelae of COVID-19
Recruiting
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. There is ongoing research and growing literature describing severe acute respiratory syndrome (SARS-COV-2). There is a growing population of individuals who have recovered from acute SARS-COV-2 infection. The long-term effects of COVID-19 are unknown. There are growing reports of sequelae after acute SARS-CoV-2 not limited to fatigue, dyspnea, reactive airway disease, organizing pneumonia, pulm... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/17/2022
Locations: Vanderbilt_University MC, Nashville, Tennessee
Conditions: Covid19, Sars-CoV-2 Infection, Dyspnea Caused by 2019-nCoV, COVID-19 Acute Respiratory Distress Syndrome, Pulmonary Fibrosis
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis. Finding the genes that cause pulmonary fibrosis is the first step at developing better methods for early diagnosis and improved treatment for pulmonary fibrosis. The overall hypothesis is that inherited genetic factors predispose individuals to develop pulmonary fibrosis... Read More
Gender:
All
Ages:
All
Trial Updated:
09/11/2020
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia